Clinical Trials · global
Breast Cancer Trial Adapts to Treatment Changes: BioNTech Plans to Combine Trodelvy With a Bispecific Antibody
ROSETTA Breast-01 plans to use an antibody-drug conjugate as its treatment backbone to test whether adding pumitamig can further improve survival in patients with advanced triple-negative breast cancer. The trial amendment remains subject to regulatory approval, and the benefits and risks of the combination have yet to be established.
As cancer treatment options change, ongoing clinical trials must also recalibrate their benchmarks. BioNTech announced on October 22 that it was collaborating with Gilead on plans to amend the Phase 3 ROSETTA Breast-01 trial, replacing the original chemotherapy regimen with Trodelvy to study whether adding the novel bispecific antibody pumitamig can provide greater benefits for patients with advanced triple-negative breast cancer whose PD-L1 expression is low or negative.
The study evaluates first-line treatment in patients with locally advanced or metastatic disease and a PD-L1 combined positive score (CPS) below 10. According to Reuters, the amended trial would compare “pumitamig plus Trodelvy” with “Trodelvy alone,” replacing the original design comparing “pumitamig plus chemotherapy” with “chemotherapy alone.” However, the change still requires regulatory approval and cannot yet be considered an implemented protocol.
The change in benchmark follows the availability of a new first-line treatment option. According to BioPharm International, on June 24, 2026, the U.S. Food and Drug Administration approved Trodelvy monotherapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy. For this trial, the question therefore shifts to how much additional benefit pumitamig can provide on top of an available new treatment.
The two drugs take different approaches to attacking cancer. Pumitamig, jointly developed by BioNTech and Bristol Myers Squibb (BMS), targets both PD-L1 and VEGF-A; it is designed to improve antitumor immune responses and inhibit the formation of blood vessels that supply tumors. Trodelvy, whose generic name is sacituzumab govitecan, is an antibody-drug conjugate (ADC) targeting TROP2. Whether combining the two can translate their different mechanisms into better clinical outcomes is the question the trial seeks to answer.
BioPharm International noted that ROSETTA Breast-01 currently plans to enroll 558 participants, with progression-free survival and overall survival as its primary endpoints, measuring the time before disease progression or death and how long patients survive, respectively. These are the currently announced study plans; the final arrangements following the amendment remain subject to the approved protocol. Under the collaboration agreement, BioNTech will continue to sponsor and lead the trial, while Gilead will supply Trodelvy.
This announcement marks a change in the study’s direction; no Phase 3 efficacy results for the combination are yet available. BioNTech also explicitly stated that the combination’s safety and efficacy have not been established. Although Trodelvy already has approved uses, whether adding pumitamig extends survival, and how much it increases side effects, must still be answered by clinical data from the combination itself.